The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world treatment patterns and biomarker use in patients aged ≥65 yrs with CLL/SLL from 2020-2024
Paul Hampel, MD, Mayo Clinic, Rochester, MN, discusses real-world treatment patterns and biomarker use among patients aged ≥65 years with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from 2020 to 2024. He highlights increasing adoption of BTK inhibitors, the ongoing use of less optimal therapies, and persistent gaps in biomarker testing, underscoring the need to align treatment decisions with disease biology. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
